Stocktoria
RECURSION PHARMACEUTICALS, INC. RXRX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-04-16
RECURSION PHARMACEUTICALS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -867.9% | -814.1% | -785.3% | -616.7% | -1795.8% |
| Net margin | -863.4% | -788.0% | -736.0% | -601.0% | -1832.2% |
| FCF margin | -506.5% | -633.7% | -672.4% | -302.6% | -1949.4% |
| Return on assets | -43.7% | -32.0% | -50.2% | -34.1% | -30.6% |
| Return on equity | -57.0% | -44.8% | -70.8% | -49.3% | -34.3% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 5.50 | 3.81 | 4.70 | 5.68 | 11.46 |
| Revenue growth | 26.9% | 32.0% | 11.9% | 291.5% | 156.9% |
Source: SEC EDGAR filings · CIK 0001601830 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.